01—Abstract
Summary
Summary of the 10-K filed February 22, 2023. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported fiscal 2022 total revenue of $3.98 billiona, up from $3.54 billion in 2021, an increase of $435.9 million, or 12.3%.
Growth was led by the Discovery and Safety Assessment (DSA) segment, which generated $2.45 billionb of revenue (up 16.1%) and operating income of $532.9 million (21.8% of revenue). Research Models and Services (RMS) revenue was $739.2 million and Manufacturing revenue was $789.6 million. Consolidated operating income was $651.0 million (16.4% of revenue, down from 16.7%), and net income attributable to common shareholders rose to $486.2 million, or $9.48 diluted EPS.
The result was aided by a $123.4 millionc gain on the divestiture of the Avian Vaccine Services business, completed in December 2022, and by a 53rd week in fiscal 2022 that the filing says contributed to revenue in each segment. The filing's most significant new matter is an investigation by the U.S. Department of Justice and U.S. Fish and Wildlife Service into the company's conduct regarding several shipments of non-human primates from Cambodia. The company received a grand jury subpoena on February 17, 2023, and says it is cooperating and believes the concerns are without merit.
It has voluntarily suspended future Cambodia-sourced non-human primate shipments, and the inventory related to recent shipments carries an approximate value of $20 milliond. The company cannot predict the timing, outcome or possible fines, penalties or liabilities. Cash flow from operations declined to $619.6 million from $760.8 million, mainly due to working capital changes, and total debt and finance leases were $2.7 billion at year-end, with $3.0 billion of revolving credit capacity and $1.2 billion drawn.
The company also completed the acquisition of Explora BioLabs in April 2022 for $284.5 million and agreed to acquire SAMDI Tech in January 2023 for a preliminary purchase price of $60 million. Backlog stood at approximately $3.1 billion for DSA, $282 million for RMS and $116 million for Manufacturing at year-end 2022. The company did not repurchase shares under its program in the fourth quarter and had $129.1 million remaining authorization.
02—Key points
Key Highlights
- Total revenue rose 12.3% to $3.98 billion in fiscal 2022, driven by DSA segment growth of 16.1% to $2.45 billion.
- Operating income was $651.0 million (16.4% of revenue), compared with $589.9 million (16.7%) in fiscal 2021; the margin decline reflects higher amortization, CDMO operating costs and staffing costs.
- Net income attributable to common shareholders increased to $486.2 million ($9.48 diluted EPS) from $391.0 million, helped by a $123.4 million gain on the Avian Vaccine Services divestiture.
- DOJ and USFWS opened an investigation into shipments of Cambodia-sourced non-human primates; the company has voluntarily suspended future shipments from Cambodia and cannot predict the outcome, including any fines or penalties.
- Operating cash flow fell to $619.6 million from $760.8 million, mainly due to working capital timing and higher inventory purchases.
- Total debt and finance leases were $2.7 billion at year-end 2022, with $1.2 billion drawn on a $3.0 billion revolving credit facility.
- Year-end 2022 backlog was approximately $3.1 billion for DSA, $282 million for RMS and $116 million for Manufacturing, and the company completed the Explora BioLabs acquisition for $284.5 million.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 22, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $3.98B$3.54B | +12.3% |
| SG&A Expenses | $665.10M$619.92M | +7.3% |
| Operating Income | $650.98M$589.86M | +10.4% |
| Interest Expense | $59.29M$73.91M | −19.8% |
| Net Income | $486.23M$390.98M | +24.4% |
| EPS (Basic) | $9.57$7.77 | +23.2% |
| EPS (Diluted) | $9.48$7.60 | +24.7% |
| Shares Outstanding (Basic) | 50.81M50.29M | +1.0% |
| Shares Outstanding (Diluted) | 51.30M51.42M | −0.2% |
05—Questions
Frequently Asked Questions
What is the main legal risk disclosed in this filing?
The company was informed on February 16, 2023, that the U.S. Department of Justice, with the U.S. Fish and Wildlife Service, had begun an investigation into its conduct regarding several shipments of non-human primates from Cambodia, and it received a grand jury subpoena on February 17, 2023. The company says it is cooperating and believes the concerns are without merit, but it cannot predict the timing, outcome or possible fines, penalties or liabilities.
How did the company's supply of non-human primates change?
The company voluntarily suspended future shipments of non-human primates from Cambodia until it and USFWS can agree on and implement procedures to reasonably ensure the animals are purpose-bred. It has also agreed to continue caring for Cambodia-sourced animals from certain recent shipments already in the United States, whose inventory carrying value is approximately $20 million.
What drove revenue growth in fiscal 2022?
Revenue grew $435.9 million, or 12.3%, to $3.98 billion. The filing attributes this mainly to increased demand in the DSA segment, the impact of the 53rd week, and recent acquisitions, partly offset by divestitures of RMS Japan and CDMO Sweden and the negative effect of foreign currency changes.
Why did operating margin decline even as revenue grew?
Operating income margin fell to 16.4% from 16.7%. The filing cites higher amortization of intangible assets from recent acquisitions, higher operating costs at the CDMO business, higher staffing costs and modest inflationary pressures.
Did the company return capital to shareholders in 2022?
The company did not pay cash dividends and did not repurchase shares under its $1.3 billion stock repurchase program during fiscal 2022, leaving $129.1 million of authorization remaining at year-end. It did purchase $38.7 million of shares through netting of stock-based award tax withholding.
06—Continue